[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.197.65.227. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 684
Citations 0
Comment & Response
January 6, 2015

Management of Patients With Sickle Cell Disease—Reply

Author Affiliations
  • 1Department of Research and Education, Olmsted Medical Center, Rochester, Minnesota
  • 2University of Texas Southwestern Medical Center, Dallas
  • 3University of Colorado, Denver
JAMA. 2015;313(1):91-92. doi:10.1001/jama.2014.15909

In Reply Dr Pollack is concerned about the lack of evidence for deferasirox therapy in people with SCD and iron overload, as well as potential adverse effects and high costs. He refers to recent advances in the understanding of hepatic pathophysiology in handling iron and comments that this may apply to people with thalassemia, correctly pointing out that it is not clear if those data also apply to patients with SCD.1

First Page Preview View Large
First page PDF preview
First page PDF preview
×